| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a dose-dependent way, PCSK9-IN-10 (compound 3s) (0, 2.5, 5, 12.5, 25 µM; 24 h) dramatically decreases PCSK9 protein expression while increasing LDL receptor (LDLR) expression [1].
|
|---|---|
| ln Vivo |
In ApoE KO mice, PCSK9-IN-10 (30 mg/kg; oral; once daily for 8 weeks) decreases the amount of atherosclerotic plaque and total cholesterol (TC)[1].
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: HepG2 cells Tested Concentrations: 0-1000 µM Incubation Duration: 24 h Experimental Results: demonstrated low cytotoxicity to HepG2 cells. Western Blot Analysis[1] Cell Types: HepG2 cells Tested Concentrations: 0, 2.5, 5, 12.5, 25 µM Incubation Duration: 24 h Experimental Results: Dramatically diminished PCSK9 protein level in a dose dependent manner. |
| Animal Protocol |
Animal/Disease Models: Eight weeks old male ApoE KO mice[1]
Doses: 30 mg/kg Route of Administration: Po; one time/day for 8 weeks Experimental Results: Inhibited both hepatic and serum PCSK9 content obviously and decreased decreased atherosclerotic plaque size. |
| References |
| Molecular Formula |
C18H23N5O4
|
|---|---|
| Molecular Weight |
373.406323671341
|
| Exact Mass |
373.175
|
| CAS # |
368434-98-4
|
| PubChem CID |
3769828
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
548
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(CC2=CC=CC(OC)=C2)C2=C(N(C)C(=O)N(C)C2=O)N=C1NCCOC
|
| InChi Key |
YUNMPASCLGGSKE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H23N5O4/c1-21-15-14(16(24)22(2)18(21)25)23(17(20-15)19-8-9-26-3)11-12-6-5-7-13(10-12)27-4/h5-7,10H,8-9,11H2,1-4H3,(H,19,20)
|
| Chemical Name |
8-(2-methoxyethylamino)-7-[(3-methoxyphenyl)methyl]-1,3-dimethylpurine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 250 mg/mL (669.51 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6780 mL | 13.3901 mL | 26.7802 mL | |
| 5 mM | 0.5356 mL | 2.6780 mL | 5.3560 mL | |
| 10 mM | 0.2678 mL | 1.3390 mL | 2.6780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
